Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Tumor cell membrane disruption" refers to the breakdown of the plasma membrane integrity in cancer cells, leading to cell death. This effect can be caused by various therapeutic agents, particularly anticancer peptides (AMPs, ACPs), that exploit differences in cancer cell membrane composition—such as higher negative charge, lower cholesterol content, and altered microvilli structures—to selectively interact with and destabilize tumor but not normal cell membranes. Disruption occurs via pore formation, membrane destabilization, or lytic mechanisms, ultimately resulting in necrosis or apoptosis depending on the agent and mode of action. While it is a valuable anticancer strategy, it is not a canonical molecular target, but a therapeutic approach or effect.
Induction of plasma membrane permeabilization via direct interaction with the lipid bilayer (“barrel-stave”, “carpet”, and pore-forming models). Ion channel formation (permitting leakage of ions). Triggering necrotic or apoptotic cell death through loss of membrane integrity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor cell membrane disruption.